Juno Therapeutics Price Target Cut From $63 To $39 At JPMorgan - Benzinga

Juno Therapeutics Price Target Cut From $63 To $39 At JPMorgan Benzinga Juno Therapeutics Inc JUNO has placed its lead CAR-T [pivotal Phase 2 ROCKET trial evaluating JCAR015 in adult ALL] on clinical hold after 2 patient deaths. JPMorgan's Cory Kasimov downgraded the rating on the company from Overweight to Neutral, ... and more »

from Health - Google News http://news.google.com/news/url?sa=t&fd=R&ct2=us&usg=AFQjCNE-3WEMxtM9aYrCq2ki6gPpPy681g&clid=c3a7d30bb8a4878e06b80cf16b898331&cid=52779151630272&ei=VON_V5jEOsW-3gHi7KSQCw&url=http://www.benzinga.com/analyst-ratings/analyst-color/16/07/8197495/juno-therapeutics-price-target-cut-from-63-to-39-at-jpmo
via IFTTT